Brief: Ironwood Pharmaceuticals - Maintains Full Year 2023 Guidance

Ironwood Pharmaceuticals

09/11/2023 12:31

Nov 9 (Reuters) - Ironwood Pharmaceuticals Inc  IRWD.O :
    * MAINTAINS FULL YEAR 2023 GUIDANCE
    * EXPECTS TOPLINE DATA FOR PHASE II STUDY OF CNP-104 IN
PRIMARY
BILIARY CHOLANGITIS (PBC) IN Q3 OF 2024
    * TOTAL REVENUES IN Q3 OF 2023 WERE $113.7 MILLION
    * ENDED Q3 OF 2023 WITH $110.2 MILLION OF CASH AND CASH
EQUIVALENTS
    * QTRLY  EARNINGS PER SHARE $0.09
    * Q3 EARNINGS PER SHARE VIEW $0.16, REVENUE VIEW $112.9
MILLION --
LSEG IBES DATA

Source text for Eikon:  ID:nBw5tzFmXa 
Further company coverage:  IRWD.O 

 ((Reuters.Briefs@thomsonreuters.com;))